CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤患者的颅内 CAR-T 细胞递送
英文原题：Intracranial CAR-T cell delivery in glioblastoma patients.
查看英文原题
Intracranial CAR-T cell delivery in glioblastoma patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法正成为改善高级别胶质瘤患者结局的一种有希望的方法。本文重点介绍了近期三项研究：这些研究报告了在胶质母细胞瘤（GBM）患者中颅内给予 CAR-T 细胞的安全性和可行性，并提供了初步潜在疗效证据，支持进一步研究这一治疗策略。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.
论文信息
- 作者
- Vaughn-Beaucaire P、Choi MJ、Liang O、Lawler SE
- 第一作者单位
- Department of Pathology and Laboratory Medicine, Legoretta Cancer Center, Brown University, Providence, RI 02903, USA.United States
- 通讯作者单位
- Department of Pathology and Laboratory Medicine, Legoretta Cancer Center, Brown University, Providence, RI 02903, USA. Electronic address: Sean_lawler@brown.edus.United States
- 文献类型
- 美国 NIH 资助研究
- 期刊
- Trends in cancer2024 Jun
- 原文标识
- PubMed 38777680 · DOI 10.1016/j.trecan.2024.05.002